Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts
- 10 March 2016
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 65 (5) , 525-536
Abstract
We studied whether blockade of inhibitory receptors on cytokine-induced killer (CIK) cells by immune checkpoint inhibitors could increase its anti-tumour potency against haematological malignancies. CIK cultures were generated from seven normal donors and nine patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) or multiple myeloma (MM). The inhibitory receptors B and T lymphocyte attenuator, CD200 receptor, lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin and mucin-domain-containing-3 (TIM-3) were present at variable percentages in most CIK cultures, while cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1) and killer cell immunoglobulin-like receptors (KIR2DL1/2/3) were expressed at low level in most cultures. Without blockade, myeloid leukaemia cells were susceptible to autologous and allogeneic CIK-mediated cytotoxicity. Blockade of KIR, LAG-3, PD-1 and TIM-3 but not CTLA-4 resulted in remarkable increase in killing against these targets, even in those with poor baseline cytotoxicity. ALL and MM targets were resistant to CIK-mediated cytotoxicity, and blockade of receptors did not increase cytotoxicity to a meaningful extent. Combination of inhibitors against two receptors did not further increase cytotoxicity. Interestingly, potentiation of CIK killing by blocking antibodies was not predicted by expression of receptors on CIK and their respective ligands on the targets. Compared to un-activated T and NK cells, blockade potentiated the cytotoxicity of CIK cells to a greater degree and at a lower E:T ratio, but without significant increase in cytotoxicity against normal white cell. Our findings provide the basis for clinical trial combining autologous CIK cells with checkpoint inhibitors for patients with AML.Keywords
Funding Information
- SGH Research Fund (SRG/C3/03/2014)
This publication has 46 references indexed in Scilit:
- Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal TumorsJournal of Immunology Research, 2014
- Human interferon-alpha increases the cytotoxic effect of CD56+cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell linesCytotherapy, 2012
- Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumorsExpert Opinion on Biological Therapy, 2012
- New adoptive immunotherapy strategies for solid tumours with CIK cellsExpert Opinion on Biological Therapy, 2012
- The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cellsCytotherapy, 2012
- Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptorsHaematologica, 2010
- Cytokine‐induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon‐γInternational Journal of Cancer, 2006
- Generation of cytokine‐induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blastsBritish Journal of Haematology, 2002
- Expansion of Philadelphia Chromosome–Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease MiceBlood, 1998
- Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.Journal of Experimental Medicine, 1991